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s u m m a r y 
Background and rationale: Some studies of hospitalized patients suggested that the risk of death and/or 
severe illness due to COVID-19 is not associated with the use of angiotensin-converting enzyme inhibitors 
(ACEIs) and/or angiotensin II receptor type 1 blockers (ARBs). Nevertheless, some controversy still exists 
and there is limited information of the ACEIs/ARBs effect size on COVID-19 prognosis. 
Aim and Methods: We aimed to measure the effect of ACEIs and/or ARBs on COVID-19 severe clinical 
illness by a meta-analysis. Literature search included all studies published since the COVID-19 outbreak 
began (December 2019) until May 9, 2020. We analyzed information from studies that included tested 
COVID-19 patients with arterial hypertension as comorbidity prior to hospital admission and history of 
taking ACEIs, ARBs, or ACEIs/ARBs. 
Results: We included 16 studies that involved 24,676 COVID-19 patients, and we compared patients with 
critical ( n = 4134) vs. non-critical ( n = 20,542) outcomes. The overall assessment by estimating random 
effects shows that the use of ACEIs/ARBs is not associated with higher risk of in-hospital-death and/or 
severe illness among hypertensive patients with COVID-19 infection. On the contrary, effect estimate 
shows an overall protective effect of RAAS inhibitors/blockers (ACEIs, ARBs, and/or ACEIs/ARBs) with ∼
23 % reduced risk of death and/or critical disease (OR: 0.768, 95%CI: 0.651-0.907, p = 0.0018). The use of 
ACEIs (OR:0.652, 95%CI:0.478-0.891, p = 0.0072) but not ACEIs/ARBs (OR:0.867, 95%CI:0.638-1.179, p = NS) 
or ARBs alone (OR:0.810, 95%CI:0.629-1.044, p = NS) may explain the overall protection displayed by RAAS 
intervention combined. 
Conclusion: RAAS inhibitors might be associated with better COVID-19 prognosis. 
© 2020 The British Infection Association. Published by Elsevier Ltd. All rights reserved. 
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Although COVID-19 pandemic is only a few months old, the
agnitude of clinical information regarding the disease spectrum
s overwhelming. ACE2 (angiotensin-converting enzyme 2) is pre-
umably the host receptor of the novel SARS-CoV-2 coronavirus. 1 
lthough the effect is significantly reduced by adjusting by age, 2 
rterial hypertension seems to be one of the most common risk
actor associated with COVID-19 mortality, 3 , 4 . In fact, 56.6% of a∗ Corresponding authors: Carlos J. Pirola, Ph.D. and Silvia Sookoian, M.D., 
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Journal of Infection, https://doi.org/10.1016/j.jinf.2020.05.052 ase series of 5700 patients with COVID-19 admitted to 12 hos-
itals in New York City 3 and 30% of patients with COVID-19 in
uhan, China 4 presented arterial hypertension as comorbidity. 
Therefore, the effect/s of angiotensin-converting enzyme in-
ibitors (ACEIs) and/or angiotensin II receptor type 1 blockers
 ARBs ) on the clinical course of the disease have been on the top
f clinical debates owing to the putative regulation of ACE2 exerted
y these drugs. 5 
Four large studies, including hospitalized patients from Eu-
ope and USA 6–9 convincingly demonstrated that the risk of severe
OVID-19 and/or in-hospital death among those infected is not as-
ociated with the use of ACEIs and/or ARBs. Likewise, results from
arge studies from Asia suggested that it is unlikely that in-hospital
se of ACEIs/ARBs is associated with increased COVID-19 mortality
isk. 10 , 11 eserved. 
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i  While the evidence shows consistent results, there is limited in-
formation on the ACEIs/ARBs effect size on the COVID-19 progno-
sis. Hence, the primary objective of the current study is to provide
a quantitative estimation of the effect of ACEIs and/or ARBs, alone
or ACEIs/ARBs (undistinct drug) on COVID-19 severe clinical illness
in patients with arterial hypertension by a meta-analysis. 
Methods 
We followed the appropriate method for conducting a meta-
analysis of observational studies (MOOSE) ( Supplementary Table
S1 ). 
Search strategy 
The literature search included all studies published since the
COVID-19 outbreak began (December 2019) until May 9, 2020, with
no country restrictions imposed. To identify studies for inclusion in
the meta-analysis, we searched for published studies on PubMed,
Ovid-Medline and Google Scholar using the following query: (RAAS
OR ACE OR angiotensin-converting enzyme OR ACE OR ATR1 OR
angiotensin II receptor type 1 OR ATR OR AGTR1 OR AGT1R) AND
(inhibitor ∗ OR blocker ∗) OR (ACEI ∗ OR ARBs OR lisinopril OR fos-
inopril OR losartan OR irbesartan OR ramipril OR olmesartan OR
perindopril OR captopril OR telmisartan) OR hypertension AND
(coronavirus OR SARS OR COVID-19 OR SARS-CoV ∗) AND (clinical
OR outcomes OR death ∗ OR hospitalization ∗) AND (2019 OR 2020).
Besides, we performed a search in online repositories under the
following terms: “COVID-19 AND hypertension AND RAAS”. 
Details of the search strategy and included studies are shown in
Supplementary Figure S1 . The authors (CJP and SS) reviewed all
abstracts independently to determine the alignment with the eli-
gibility criteria, or to establish the appropriateness of the research
topic. If these criteria were met, the article was retrieved and re-
viewed in its entirety. There were no discrepancies in this process.
Inclusion and Exclusion Criteria and Data Collection 
The following meta-analysis inclusion criteria were considered
when assessing the eligibility of the identified studies: 
Observational studies of hospitalized patients with confirmed
COVID-19 infection that: 1) included COVID-19 patients with ar-
terial hypertension as comorbidity prior to hospital admission and
history of taking ACEIs, ARBs or ACEIs/ARBs (the Authors did not
disclose individual drug information) at the time of COVID-19 test-
ing, and 2) disclosed information on clinical outcomes defined as
critical or fatal versus non-critical disease. 
Statistical Analysis 
A random effect model was adopted when summarising statis-
tical synthesis; this model assumes that the treatment effect is not
the same across all studies included in the analysis. 
For each analysis, a forest plot was generated to display results.
Heterogeneity was evaluated via the Q statistic and I 2 statistic,
which is a transformation of Q that estimates the percentage of
the variation in effect sizes that is due to heterogeneity. As an I 2 
value of 0% indicated no observed heterogeneity, greater values de-
noted increasing heterogeneity. Subgroup analyses were performed
to determine the presence of potential heterogeneity sources. We
identified characteristics that allowed the studies to be stratified
into subsets with homogeneous effects. As we hypothesized that
the RAAS inhibitor class, ethnicity, and peer-reviewed process may
provide an important source of variability, the estimate of the aver-
age effect of the studies was additionally stratified by these mod-
erator variables. Please cite this article as: C.J. Pirola and S. Sookoian, Estimation of R
Journal of Infection, https://doi.org/10.1016/j.jinf.2020.05.052 To identify studies yielding findings that had a disproportion-
tely significant influence on the effect estimate, we repeated the
nalysis after removing one study at a time. 
We performed a visual inspection of funnel plots, but publica-
ion bias was formally tested by using the Begg and Mazumdar’s
ank correlation test and Egger’s method. 
Statistical significance was assumed for p ≤ 0.05. 
All calculations were performed using the Comprehensive
eta-Analysis computer program (Biostat, Englewood, NJ, USA). 
ssessment of Study Quality 
The quality of the studies included in the meta-analysis was as-
essed using The Newcastle-Ottawa Scale (NOS) ( Supplementary
able S2 ). 
esults 
tudy selection 
Following the previously described search strategy, 29 articles
ere initially identified as potentially relevant for the present in-
estigation, based on the assessment of the titles and abstracts.
e excluded thirteen studies because they did not meet all the
nclusion criteria ( Supplementary Figure S1 ). Thus, the remaining
6 studies were included in the meta-analysis, 3 , 6–20 which scored
ell in terms of the selection criteria, comparability of critical and
on-critical COVID-19 on the basis of the design or analysis, and
scertainment of exposure ( Supplementary Table S2 ). 
tudy Characteristics 
We included 16 studies that involved 24,676 COVID-19 pa-
ients, and we compared patients with critical ( n = 4134) vs. non-
ritical ( n = 20,542) outcomes. The study characteristics, including
he clinical criterion used for the differentiation between critical
nd non-critical patients, are shown in Table 1 . All 16 studies in-
luded adult patients of both sexes, mean/median estimated age
anging from 50 to > 70 years. Eight studies included patients from
hina, 10 , 11 , 15–18 , 20 , 21 four studies included patients from North
merica, 3 , 8 , 9 , 12 three studies included patients from Europe, 6 , 13 , 14 
nd one study included data extracted from an international reg-
stry. 7 Complete details of the study design and sample sizes are
ully disclosed in Table 1 . 
stimation of effect sizes of RAAS inhibitors/blockers 
The overall assessment by estimating random effects shows
hat the use of ACEIs/ARBs is not associated with a higher risk
f in-hospital death and/or severe illness among hypertensive pa-
ients with COVID-19 infection. On the contrary, the effect esti-
ates show an overall protective effect by RAAS inhibition (ACEIs,
RBs, or ACEIs/ARBs) of ∼ 23 % reduced risk of death and/or criti-
al disease (OR: 0.768, 95%CI: 0.651-0.907, p = 0.0018) ( Figure 1 ). 
Of note, the use of ACEIs (OR:0.652, 95%CI:0.478-0.891,
 = 0.0072) but not ACEIs/ARBs (OR:0.867, 95%CI:0.638-1.179, p
 NS) or ARBs alone (OR:0.810, 95%CI:0.629-1.044, p = NS) may con-
er a significant ∼ 35% reduction in the risk of death/critical dis-
ase ( Supplementary Figure S2 ) and explain the overall protection
isplayed by RAAS inhibition combined. 
Overall heterogeneity as assessed by the Q statistics ( p = 0.0 0 01,
 
2 = 63.1) was not mitigated by grouping studies by ACEI, ARBs,
r the indistinct drug (ACEIs/ARBs) ( p = 0.004, I 2 = 66.1; p = 0.021,
 
2 = 59.8; p = 0.013, I 2 = 58.6, respectively). However, stratification of
tudies by country of origin showed a significant heterogeneity
n the results pertaining to studies involving patients from NorthAAS-Inhibitor effect on the COVID-19 outcome: A Meta-analysis, 
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Table 1 
Characteristics of the studies included in the meta-analysis 
Author, Country. 
Journal 
Diagnosis of COVID-19 (details 
as specified by the authors) 
Setting and study design. Total sample 
size ( n ) 
Inclusion criterion for critical 
or fatal infection 
Non-severe/ Death or 
critical illness ( n ) 
Mancia G, Italy. 
NEJM 
Positive nasopharyngeal swab 
specimens tested with 
real-time 
reverse-transcriptase–
polymerase-chain-reaction 
assays 
Population-based case–control 
study of patients older than 
40 years; Lombardy region. 
6272 Received assisted ventilation 
or died 
5655/617 
Mehra MR Asia, 
Europe, and 
North America. 
NEJM 
Positive result on high 
throughput sequencing or 
real-time 
reverse-transcriptase–PCR 
assay of nasal or pharyngeal 
swab specimens. 
Data extracted from an 
international registry 
involving 169 hospitals in 
11 countries. 
8910 Recorded in the registry as 
having died in the hospital 
8395/515 
Reynolds HR 
North America. 
NEJM 
Positive for SARS-CoV-2 RNA Observational study; 
inpatients in the NYU 
Langone Health system. 
2408 Admission to the intensive 
care unit; use of invasive or 
noninvasive mechanical 
ventilation, or death. 
1195/1213 
Li J 
China. 
JAMA Cardiol 
Real-time reverse transcription 
polymerase chain reaction 
Retrospective, single-center 
case series Central Hospital 
of Wuhan (Hubei Province, 
China) 
362 One of the following: blood 
oxygen saturation levels of 
93% or less, respiratory 
frequency of 30/min or 
greater, a partial pressure of 
arterial oxygen to fraction of 
inspired oxygen ratio of less 
than 300, lung infiltrates 
more than 50% within 24 to 
48 hours, septic shock, 
respiratory failure, and/or 
multiple organ dysfunction 
or failure. 
247/115 
Yang G 
China. 
Hypertension 
Confirmed COVID-19 according 
to the guideline of 
SARS-CoV-2 (The Fifth Trial 
Version of the Chinese 
National Health 
Commission) 
Retrospective, single-center 
study. 
126 One of the following: 
Respiratory failure and 
mechanical ventilation; 
shock; other organ failure 
that requires intensive care 
unit care 
83/43 
Zhang P 
China 
Cir Res 
Reverse transcription 
polymerase chain reaction 
according to the guideline of 
SARS-CoV-2 (The Fifth Trial 
Version of the Chinese 
National Health 
Commission) 
Retrospective, multi-center 
study; patients aged from 
18 to 74 years. 
1650 All-cause death. ARDS and 
septic shock 
1288/362 
Andrew Ip 
North 
America. 
medRxiv 
Confirmed SARS-CoV-2 
(methods not specified). 
Retrospective, multicenter 
study; Hackensack Meridian 
Health network New Jersey. 
1129 Death 669/460 
Feng Y 
China. 
Am J Respir Crit 
Care Med 
Throat-swab specimens from 
the upper respiratory tract; 
real-time reverse 
transcription polymerase 
chain reaction assay. 
Multi-center retrospective 
study involving three 
hospitals in Wuhan, 
Shanghai and Anhui. 
97 One of the following 
conditions: (1) Respiratory 
failure and mechanical 
ventilation is required;(2) 
Shock;(3) Patients with 
other organ dysfunction 
needing intensive care unit 
62/35 
Guo T 
China. 
JAMA Cardiol 
Interim guidance of the World 
Health Organization. 
Retrospective single-center 
case series; electronic 
medical records 
187 Death 168/19 
Liu Y 
China. 
medRxiv 
Guidelines of 2019-CoV 
infection from the National 
Health Commission of the 
People’s Republic of China. 
Multicentre retrospective 
study; medical records of 
three cohorts (adult patients 
≥18 years old). 
46 The guidelines of 2019-nCoV 
infection from the National 
Health Commission of the 
People’s Republic of China. 
18/28 
Mehta N 
North 
America. 
JAMA Cardiol 
Nasopharyngeal and 
oropharyngeal swab 
specimens with SARS-CoV-2 
confirmed by laboratory 
testing using the Centers for 
Disease Control and reverse 
transcription–polymerase 
chain reactionSARS-CoV-2 
assay. 
Retrospective cohort analysis 
of a prospective, 
observational study; 
Cleveland Clinic Health 
System in Ohio and Florida 
1705 Patients admitted to an ICU; 
patients who required 
mechanical ventilation/ 
death 
1494/211 
Meng J 
China. Emerg 
Microbes Infect 
A commercial real-time PCR 
kit (GeneoDX Co., Ltd., 
Shanghai, China) 
Retrospective analysis 
of medical records; 
Shenzhen Third People’s 
Hospital 
42 Guidelines established by the 
National Health Commission 
of the People’s Republic of 
China. 
25/17 
( continued on next page ) 
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Table 1 ( continued ) 
Author, Country. 
Journal 
Diagnosis of COVID-19 (details 
as specified by the authors) 
Setting and study design. Total sample 
size ( n ) 
Inclusion criterion for critical 
or fatal infection 
Non-severe/ Death or 
critical illness ( n ) 
Richardson S 
North 
America. 
JAMA 
Positive result on polymerase 
chain reaction testing of a 
nasopharyngeal sample. 
Case series COVID-19 
hospitalized patients; 
Northwell Health academic 
health system in New York. 
1366 Death 982/384 
Zeng Z 
China. 
medRxiv 
Clinically confirmed COVID-19 
and RT-PCR assay 
Single-center, retrospective, 
observational study (Hankou 
Hospital, Wuhan) 
75 Death 47/28 
Conversano A 
Italy. 
Hypertension 
Confirmed diagnosis of 
SARS-CoV-2 pneumonia by 
chest x-ray-or CT-scan and 
real-time PCR 
Retrospective, observational 
study from a single tertiary 
center (Milan); data 
obtained from electronic 
medical records. 
96 Non-survivors 62/34 
Bean D 
London. medRxiv 
Inpatients testing positive for 
SARS-Cov2 by RT-PCR 
Study cohort 205 Death or admission to a 
critical care unit for 
organ-support within 21 
days of symptoms onset. 
152/53 
Figure 1. Quantitative estimation of the effect of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor type 1 blockers (ARBs), alone or undistinct drug 
(ACEIs/ARBs) on COVID-19 severe clinical illness. Association analysis of death/critical illness vs. non-critical illness in COVID-19 patients receiving ACEIs, ARBs, or ACEIs/ARBs 
without discrimination. For the dichotomous variable (critical / non-critical), the effect denotes odds ratio (OR) and corresponding 95% confidence interval (CI). Because of 
the presence of heterogeneity, a random effect model was adopted to estimate the pooled ORs. This model assumes that the treatment effect is not the same across all 
studies included in the analysis. The first author of the study is shown under the sub-heading “study name.” Popul: indicates the use of ACEIs, ACEIs/ARBs, or ARBs. In the 
graph, the filled squares denote the effect of individual studies, and filled diamonds express combined fixed and random effects. 
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T  America or Europe ( p = 0.001, I 2 = 66.8) but not from studies in-
volving patients from China ( p = 0.42, I 2 = 2.3). Surprisingly, no sig-
nificant heterogeneity was found in studies retrieved from on-
line repositories ( p = 0.42, I 2 = 0). Conversely, the heterogeneity re-
mained significant among all studies representing peer-reviewed
contributions ( p = 0.0 0 01, I 2 = 64.1). 
The removal of one study at a time shows robust estimation of
the pooled effect (estimated ORs from 0.744 (95% CI: 0.633-0.874)
to 0.813 (95% CI: 0.699-0.946), p = 0.0 0 03 to 0.0075) ( Figure 2 ). 
The Begg and Mazumdar’s rank correlation test (Kendall‘s tau
-0.23, p = 0.11) shows no publication bias. 
o  
Please cite this article as: C.J. Pirola and S. Sookoian, Estimation of R
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ummary of main findings 
Based upon the results yielded by a comprehensive analysis
f the results reported by 16 studies, we presented robust evi-
ence on the lack of association between the use of RAAS in-
ibitors/blockers and COVID-19 severe clinical illness. In addition,
ur findings demonstrated that the use of ACEIs/ARBs is associ-
ted with potential protective effects on the COVID-19 prognosis.
he analysis focused on the estimation of the individual effect size
f each group of drugs, including ACEIs, ARBs, or indistinct drugAAS-Inhibitor effect on the COVID-19 outcome: A Meta-analysis, 
C.J. Pirola and S. Sookoian / Journal of Infection xxx (xxxx) xxx 5 
ARTICLE IN PRESS 
JID: YJINF [m5G; June 3, 2020;11:34 ] 
Figure 2. Quantitative estimation of the effect of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor type 1 blockers (ARBs), alone or undistinct drug 
(ACEIs/ARBs) on COVID-19 severe clinical illness after removing the indicated study at a time. The first author of the removed study is shown under the sub-heading “study 
name.” Popul: indicates the use of ACEIs, ACEIs/ARBs, or ARBs. 
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c  ACEIs/ARBs) suggested that the protective effect of RAAS inhibitors
gainst severe COVID-19 illness may be explained by the use of
CEIs. It is worth noting, however, that none of the studies in-
luded in this meta-analysis were randomized trials. Thus, many
nmeasured confounding factors could not be assessed. 
Furthermore, retrospective analysis and data extraction from
lectronic heath records might have introduced selection bias and
or treatment misclassification, which might have artificially fa-
ored the protective effects of ACEIs for over ARBs or indistinct
rug (ACEIs/ARBs) against the development of severe COVID-19.
nother unmeasured confounding factors, for example, obesity and
everity of type 2 diabetes, are likely to influence the outcomes. 
Finally, one could speculate on any key differential effect of
CEIs on the pathophysiology of severe COVID-19. Nevertheless,
he lack of complete knowledge on the mechanism/s behind crit-
cal COVID-19 illness jeopardizes the plausibility of any biologi-
al hypothesis, including the question of whether the ACEIs or
RBs-mediated reduction of the angiotensin II production or the
T1R activation might explain the clinical observations. Both drug
lasses seem to up-regulate ACE2 expression in relevant organs, 22 
nd its implications in COVID-19 outcomes have been largely dis-
ussed. 5 , 23 
There is one remarkable aspect that could not be specifically
eighted in our meta-analysis, which is the analysis of comor-
idities and effect sizes for the individual treatment or the co-
dministration of ACEIs and ARBs in elderly patients. Patients
ith suboptimal control of blood pressure with any of the drug
lasses, included those in the reference groups (non-RAAS in-
ibitors), might also influence the explored outcomes. Please cite this article as: C.J. Pirola and S. Sookoian, Estimation of R
Journal of Infection, https://doi.org/10.1016/j.jinf.2020.05.052 imitations and strengths at study, outcome, and review level 
Some limitations of our study, which are implicit in the stud-
es included, have been mentioned but should be emphasized. In-
eed, there are limitations and potential sources of heterogeneity
mposed by the quality of the observational data. For instance, al-
hough many reports used age and sex-matched patients, potential
onfounders and selection bias, not only regarding the patients but
lso treatment comparisons could not be assessed because of in-
ufficient information. By meta-regression, the average age of the
tudied populations did not explain the results, but a nondisclosure
ifference between the age of treated and untreated with RAAS in-
ibitor groups cannot be ruled out. 
Notably, substantial heterogeneity was present within most
tudies from North America and Europe but not among studies
rom China. We could not identify the sources of heterogeneity
mong studies involving non-Asian COVID-19 patients. However,
here are many potential explanations, from differences in doses
f antiviral drugs and/or interventions for the treatment of severe
OVID-19 to differences in recruitment and timing of outcomes
easurements. 
Furthermore, characteristics of the studies (for example,
ethodological differences in the study design), or even differ-
nces at the population level (such as unknown environmental fac-
ors and/or underlying disease comorbidities), are certainly highly
mportant variables that may explain the heterogeneity of the
ataset as a whole. 
Unfortunately, as the authors of a large majority of studies in-
luded in the meta-analysis did not report the findings for maleAAS-Inhibitor effect on the COVID-19 outcome: A Meta-analysis, 
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2  and female patients separately, we were unable to perform strati-
fication of the results by sex. Consequently, the potential presence
of sexual dimorphism could not be explored. Likewise, the effect
of potential confounder risk factors, such as obesity and/or type 2
diabetes, which might probably co-exist with arterial hypertension,
could not be assessed as potential source of heterogeneity because
of lack of information in the original studies. Finally, the quality
of the studies retrieved from online repositories might be compro-
mised because preprints are preliminary reports of work that have
not been certified by peer review. Surprisingly, sensitivity analysis
of studies published in peer-reviewed journals vs. preprint reports
showed no heterogeneity between the latter. 
Perspectives 
More studies are needed to ensure that our results can be gen-
eralizable to all populations. It seems relevant to replicate and con-
firm these findings in well-controlled studies with clear disclosure
of co-variables to provide not only accurate clinical recommenda-
tions for patients with COVID-19 but also precise estimates of the
treatment effects. 
Source of funding: This study was supported by grant num-
bers PICT 2015-0551, and PICT 2016-0135 (Agencia Nacional de
Promoción Científica y Tecnológica, FONCyT), CONICET Proyectos
Unidades Ejecutoras 2017, grant number PUE 0055. 
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